You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication Systems

    SBC: Prentke Romich Company            Topic: NIDCD

    Compatibility between Brain-Computer Interface and High Efficiency Augmentative and AlternativeCommunication Systems: Phase II ABSTRACT Brain-computer interfaces (BCI) enable text production for people who cannot move, but have only simple communication interfaces and are not widely used. Augmentative and alternative communication (AAC) systems are widely used and give efficient and precise commun ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Internet-based Fidelity Enhancement of MTFC

    SBC: Tfc Consultants, Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Biochemical Diagnosis for Creutzfeldt-Jakob disease

    SBC: Amprion, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Human prion diseases are infectious and invariably fatal forms of neurodegenerative diseases, including sporadic Creutzfeldt-Jakob disease (sCJD), the most common form, and variant CJD (vCJD) which is associated to consumption of cattle meat infected by bovine spongiform encephalopathy. Currently there is not sensitive, objective and non-invasive biochemical di ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Resonant-Photonic-Device-Enhanced SERS Substrate with Pinpointed Plasmonic-Active

    SBC: OMEGA OPTICS INC            Topic: NIEHS

    DESCRIPTION (provided by applicant): The use of Surface Enhanced Raman Scattering (SERS) for biomolecule detection has been restricted due to the great difficulty of fabricating ultrasensitive and reproducible surface-plasmonic-resonance (SPR) substrates.Therefore, detecting extremely small amount of biomolecules for clinical application is significantly limited. In this STTR Phase II research, w ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an Electromyographically Controlled Electrolarynx Voice Prosthesis

    SBC: GRIFFIN LABORATORIES, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): The most common artificial voice source for post-laryngectomy speech rehabilitation is the hand-held buzzer or electrolarynx (EL). This device is relatively easy to use and enables most laryngectomees to verbally communicate, but with reduced intelligibility and markedly degraded naturalness. In addition, EL speech is often described as robotic and monotone, at ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community Participation

    SBC: OHIO WILLOW WOOD COMPANY, THE            Topic: NICHD

    Evolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. An Interactive Informed Consent Program for Cardiac Procedures

    SBC: ARCHIE MD INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Informed consent has become an essential component of the doctor-patient interaction. The informed consent process requires that patients not only be given information about proposed medical treatment, but that it be presented in an understandable way so the patient can make meaningful choices about medical alternatives. At the heart of the informed consent doc ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. User Adaptation of AAC Device Voices

    SBC: BIOSPEECH INC            Topic: NIDCD

    DESCRIPTION (provided by applicant): Augmentative and alternative communication devices with voice output (also known as Speech Generating Devices, or SGDs) enable individuals to speak by electronic means. Typical users of SGDs are individuals who have suffered from a stroke, traumatic brain injury, or who have neurodegenerative or neurodevelopmental disorders. In most cases, the user was able to ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government